Traditional medicine has long relied on complex herbal formulas—decoctions and pills containing hundreds of distinct phytochemicals. While these treatments have been used clinically for centuries, they have historically been treated as "black boxes" by modern pharmacology. Unlike Western medicine, which typically follows a "one drug, one target" paradigm, herbal formulas operate through a "multi-component, multi-target" mode of action.
The research direction emerging from these papers focuses on network pharmacology and systems biology to decode this complexity. By mapping the interactions between diverse chemical constituents and systemic biological networks, researchers are transforming ancient remedies into evidence-based therapies.
The Multi-Component Black Box
The fundamental challenge in studying formulas like QiShenYiQi Pills (QSYQ) or the You-gui pill (YGP) is their chemical heterogeneity. A single extract can contain dozens of bioactive saponins, alkaloids, and flavonoids. Yuanyuan Chen and colleagues argue that this complexity is actually a feature, not a bug: it allows for a "division of labor" where different ingredients simultaneously repair metabolism and neutralize oxidative stress.
However, this complexity creates a pharmacokinetic nightmare. As Hai-Qiao Wang demonstrates with Rhizoma Anemarrhenae, many of these compounds have low bioavailability or undergo significant biotransformation in the gut. To understand why these formulas work, researchers must move beyond isolating single "active ingredients" and instead look at how the entire "cloud" of metabolites interacts with the body's signaling networks.
Mapping Networks via Systems Biology
To bridge the gap between traditional practice and molecular biology, researchers use a three-step computational and experimental pipeline:
- Chemical Profiling: Using high-resolution mass spectrometry (HPLC-MS/MS) to identify what is actually in the blood after ingestion. Lili Hong used this to pinpoint four specific molecules in the Ershen Zhenwu Decoction that drive its effects on heart failure.
- Network Prediction: Using deep learning models like CWI-DTI, developed by Ying Li, to predict drug-target interactions (DTIs). These models account for the high heterogeneity of herbal ingredients to find where they "dock" in human cells.
- Omics Validation: Integrating transcriptomics and metabolomics to see how the formula changes the body's global state. Jingjing Wei showed that the Yiqi Huoxue prescription works by simultaneously reprogramming energy metabolism and dampening inflammatory "traps" (NETs).
This approach reveals that herbal formulas often target "hubs" in biological networks—proteins like TNF, PI3K, and Akt that sit at the intersection of multiple disease pathways. For example, Shuiquan Li mapped compounds like berberine onto the PI3K/AKT and PD-1/PD-L1 pathways, showing how they can synergize with modern cancer immunotherapies.
Synergistic Mechanisms of Action
The intuition behind the "multi-target" approach is that complex diseases like Alzheimer’s, obesity, and heart failure are rarely caused by a single broken "switch." Instead, they are failures of entire systems.
- Metabolic Reprogramming: Formulas like Wumeishanzhayin (WMSZY) combat obesity not just by suppressing appetite, but by activating the AMPK/CPT-1 pathway to "turn up the dial" on fat oxidation across the whole body.
- The Gut-Microbiome Axis: A major recurring theme is the modulation of the gut microbiota. Donghui Li and Zizhen Qin describe how TCM ingredients reshape the microbiome to lower toxic metabolites like TMAO, which are linked to both heart disease and dementia.
- Cell Death Pathways: Recent work by Yang‐Tian Yan and Qingjie Ge has identified ferroptosis (iron-dependent cell death) as a key target for herbs like Chuanxiong Rhizoma in treating stroke and kidney disease.
From Black Box to Precision Medicine
The ultimate goal of this research is to move from "alternative medicine" to "precision pharmacology." By identifying the Effective Therapeutic Module (ETM)—a specific subset of genes and metabolites that respond to a treatment—researchers like Dandan Li can predict which patients will respond best to a multi-target drug.
This transition is supported by modern clinical trial designs. For instance, Yamin Li and others are using randomized controlled trials (RCTs) to test herbal granules as "add-ons" to standard Western treatments, proving that these multi-component mixtures can enhance visual recovery or reduce the side effects of chemotherapy. By treating the herbal formula as a structured network of interactions rather than a mysterious soup, this field is creating a new framework for treating complex, systemic diseases.